Fecal transplant may improve response to immunotherapy among patients with melanoma
Source: Healio, November 2022
Fecal microbiota transplant from healthy donors may lower primary resistance to immunotherapy with anti-PD-1 agents among patients with advanced or metastatic melanoma, results of the phase 1 MIMic trial showed.
Three-quarters of patients in the study experienced some type of clinical benefit from the combination strategy, according to findings presented during Society for Immunotherapy of Cancer Annual Meeting.
Background
Composition of a patient’s gut microbiome has previously been shown to influence response to immunotherapy, according to Saman Maleki, PhD, assistant professor in the departments of oncology, pathology and laboratory medicine, and medical biophysics at Western University.